Q32 Bio Inc. (QTTB)
QTTB moved a median of 0.00% 30 minutes after news, and -0.92% by the close. How QTTB actually reacts to news — the realized, point-in-time move the market made, measured across 212 labeled events over the last three years with zero look-ahead.
QTTB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.19% | 51% | 212 |
| 30-min | 0.00% | 50% | 212 |
| 60-min | -0.36% | 45% | 212 |
| to close | -0.92% | 44% | 209 |
| Middle 50% of QTTB reactions | -1.95% to +1.53% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 212 |
Half of all Q32 Bio Inc. news events land between -1.95% and +1.53% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How QTTB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -1.19% | 36% | +2.06% |
| Analyst downgrades | 18 | -3.00% | 39% | -24.93% |
| Coverage initiations | 32 | -1.20% | 28% | -0.33% |
| Rating reiterations | 14 | -1.16% | 43% | -1.70% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how QTTB ranks against every other measured name →
That’s how QTTB usually reacts — get an email when it moves on news →Email me when QTTB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to QTTB's baseline. Nothing else.
Recent QTTB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Q32 Bio Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -10.03% | -17.88% | |
| Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 | Press release | PR Newswire | -10.03% | -17.88% | |
| Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 | Press release | PR Newswire | +0.00% | -0.95% | |
| Form 8-K Q32 Bio Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +1.37% | -0.46% | |
| Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer | Press release | PR Newswire | +1.37% | -0.46% | |
| Q32 Bio to Participate in Upcoming September Investor Conferences | Press release | PR Newswire | -1.35% | -2.78% | |
| Form 10-Q Q32 Bio Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.43% | +2.10% | |
| Form 8-K Q32 Bio Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | +2.10% | |
| Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.43% | +2.10% | |
| Form EFFECT Q32 Bio Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.96% | -7.28% | |
| Form S-3 Q32 Bio Inc. | SEC filing · Form S-3 | SEC EDGAR | +1.57% | +2.45% | |
| Form 8-K Q32 Bio Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -2.38% | -4.88% | |
| Form EFFECT Q32 Bio Inc. | SEC filing · Form EFFECT | SEC EDGAR | +3.45% | -13.13% | |
| Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | PR Newswire | -1.40% | -13.97% | |
| Form 8-K Q32 Bio Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +4.37% | +16.77% | |
| Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata | Press release | PR Newswire | +4.37% | +16.77% | |
| Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | PR Newswire | +3.45% | -13.13% | |
| Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 | Press release | PR Newswire | +4.37% | +16.77% | |
| Form S-3 Q32 Bio Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.08% | +9.75% | |
| Form 8-K Q32 Bio Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | +1.65% | |
| Form 8-K Q32 Bio Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -3.81% | -12.11% | |
| Q32 Bio Announces $55 Million Private Placement Financing | Press release | PR Newswire | +21.05% | +40.13% | |
| Form 10-Q Q32 Bio Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.18% | +1.98% | |
| Form 8-K Q32 Bio Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +2.18% | +1.98% | |
| Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +2.18% | +1.98% | |
| Form ARS Q32 Bio Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.36% | +0.36% | |
| Form DEF 14A Q32 Bio Inc. For: Jun 12 | SEC filing · Form DEF | SEC EDGAR | -0.36% | +0.36% | |
| Form DEFA14A Q32 Bio Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.36% | +0.36% | |
| Form 8-K Q32 Bio Inc. For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | -6.93% | +2.43% | |
| Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference | Press release | PR Newswire | -0.16% | -10.33% | |
| Form 8-K Q32 Bio Inc. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +4.99% | -15.84% | |
| Form 10-K Q32 Bio Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.88% | +17.45% | |
| Form 8-K Q32 Bio Inc. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +5.88% | +17.45% | |
| Form S-8 Q32 Bio Inc. | SEC filing · Form S-8 | SEC EDGAR | +5.88% | +17.45% | |
| Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +5.88% | +17.45% | |
| Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | PR Newswire | +1.43% | -3.80% | |
| Form 8-K Q32 Bio Inc. For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +1.43% | -3.80% | |
| Q32 Bio Announces $10.5 Million Registered Direct Offering | Press release | PR Newswire | -0.84% | +8.91% | |
| Form 8-K Q32 Bio Inc. For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | +1.19% | +3.06% | |
| Form 8-K Q32 Bio Inc. For: Nov 28 | SEC filing · Form 8-K | SEC EDGAR | +10.94% | -10.12% | |
| Q32 Bio Sells Complement Inhibitor ADX-097 | Press release | PR Newswire | +10.94% | -10.12% | |
| Form 10-Q Q32 Bio Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.98% | — | |
| Form 8-K Q32 Bio Inc. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -1.98% | — | |
| Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | -1.98% | — | |
| Form 8-K Q32 Bio Inc. For: Oct 21 | SEC filing · Form 8-K | SEC EDGAR | +3.82% | -12.65% | |
| Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata | Press release | PR Newswire | +3.82% | -12.65% | |
| Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference | Press release | PR Newswire | +0.29% | +2.91% | |
| Form 10-Q Q32 Bio Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.05% | +2.63% | |
| Form 8-K Q32 Bio Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.05% | +2.63% | |
| Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +2.05% | +2.63% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the QTTB section they belong to.
Where else QTTB is measured.
QTTB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Q32 Bio Inc.'s median reaction calculated?
Every labeled QTTB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 212 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of QTTB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does QTTB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.